Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF

European Journal of Cancer Prevention

Volumn 18, Issue 5, 2009, Pages 416-423

  Yuan, Shifang ^a   Shi, Changhong ^b   Han, Wei ^b   Ling, Rui ^a   Li, Nanlin ^a   Wang, Ting ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Granulocyte macrophage colony stimulating factor; Immunotherapy; MUC1; Recombinant Bacillus Calmette Gu rin vaccine; Variable number tandem repeats

Indexed keywords

BCG VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; MUCIN 1; RECOMBINANT BCG MVNTR1 CSF VACCINE; RECOMBINANT BCG MVNTR4 CSF VACCINE; RECOMBINANT BCG MVNTR8 CSF VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SCID MOUSE; TANDEM REPEAT;

ANIMALS; BCG VACCINE; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MICE; MICE, SCID; MUCIN-1; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TANDEM REPEAT SEQUENCES; VACCINES, DNA;

EID: 69749093675     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32832c3882     Document Type: Article

References (33)

1. Acres B, Apostolopoulos V, Balloul JM, Wreschner D, Xing PX, Ali-Hadji D, et al. (2000). MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 48:588-594. (Pubitemid 30004493)
2. Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA (2001). Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int Immunol 13:897-908. (Pubitemid 32685202)
3. Baldus SE, Engelmann K, Hanisch FG (2004). MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41:189-231. (Pubitemid 38765096)
4. Barletta RG, Snapper B, Cirillo JD, Connell ND, Kim DD, Jacobs WR, et al. (1990). Recombinant BCG as a candidate oral vaccine vector. Res Microbiol 141:931-939.
5. Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, et al. (2003). Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 109:300-307. (Pubitemid 36683622)
6. Chung MA, Luo Y, O'Donnell M, Rodriguez C, Heber W, Sharma S, et al. (2003). Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine. Cancer Res 63:1280-1287. (Pubitemid 36348706)
7. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, et al. (1996). Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88:202-210. (Pubitemid 26230688)
8. Gong J, Chen D, Kashiwaba M, Kufe D (1997). Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558-561. (Pubitemid 27198656)
9. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, et al. (1998). Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci U S A 95:6279-6283. (Pubitemid 28249003)
10. Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J (1996). Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 65:664-670. (Pubitemid 26092295)
11. Hanson MS, Bansal GP, Langermann S, Stover CK, Orme I (1995). Efficacy and safety of live recombinant BCG vaccines. Dev Biol Stand 84:229-236.
12. Hunter CA, Reiner SL (2000). Cytokines and T cells in host defense. Curr Opin Immunol 12:413-418.
13. Huo Y, Li B, Zhang YQ, Wang SL, Bao MS (2007). Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein. Regul Toxicol Pharm 49:63-74. (Pubitemid 47361491)
14. Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH (1997). Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 158:4591-4601. (Pubitemid 127483777)
15. Janssens JP, Verlinden I, Güngör N, Raus J, Michiels L (2004). Protein biomarkers for breast cancer prevention. Eur J Cancer Prev 13:307-317. (Pubitemid 39096084)
16. Koido S, Kashiwaba M, Chen D, Gendle S, Kufe D, Gong J (2000). Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165:5713-5719. (Pubitemid 30836183)
17. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ (1994). Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856-2860. (Pubitemid 24187762)
18. Li YX, Powel HB (2007). Translational approaches for the prevention of estrogen receptor-negative breast cancer. Eur J Cancer Prev 16:203-215. (Pubitemid 46597424)
19. Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P (2005). Cancer immunoprevention. Future Oncol 1:57-66.
20. Mukherjee P, Ginardi AR, Madsen CS, Sterner CJ, Adriance MC, Tevethia MJ, et al. (2000). Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol 165:3451-3456. (Pubitemid 30728205)
21. Mushenkova N, Moiseeva E, Chaadaeva A, Den Otter W, Svirshchevskaya E (2005). Antitumor effect of double immunization of mice with mucin 1 and its coding DNA. Anticancer Res 25:3893-3898. (Pubitemid 41665161)
22. Plunkett T, Graham R, Correa I, Sewell R, Miles D, Burchell J, et al. (2004). Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain. Int J Cancer 109:691-697. (Pubitemid 38410612)
23. Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, et al. (2003). Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5:690-699. (Pubitemid 40309707)
24. Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, et al. (2000). Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 23:570-580. (Pubitemid 30679333)
25. Shi C, Wang X, Zhang H, Xu Z, Li Y, Yuan L (2007). Immune responses and protective efficacy induced by 85B antigen and early secreted antigenic target-6 kDa antigen fusion protein secreted by recombinant bacille Calmette- Guérin. Acta Biochim Biophys Sin (Shanghai) 39:290-296. (Pubitemid 46625312)
26. Snyder LA, Goletz TJ, Gunn GR, Shi FF, Harris MC, Cochlin K, et al. (2006). A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 24:3340-3352.
27. Soares MM, Mehta V, Finn OJ (2001). Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166:6555-6563. (Pubitemid 32467194)
28. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LT, Bennett LT, et al. (1991). New use of BCG for recombinant vaccines. Nature 351:456-460.
29. Taylor-P J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, et al. (2002). MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7:209-221.
30. Tempero RM, VanLith ML, Morikane K, Rowse GJ, Gendler SJ, Hollingsworth MA (1998). CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol 161:5500-5506. (Pubitemid 28519113)
31. Weiss WR, Ishii KJ, Hedstrom RC, Sedegah M, Ichino M, Barnhart K, et al. (1998). A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 161:2325-2332. (Pubitemid 28397045)
32. Yamamoto K, Ueno T, Kawaoka T, Hazama S, Fukui M, Suehiro Y, et al. (2005). MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 25:3575-3579. (Pubitemid 41105243)
33. Zhang S, Graeber LA, Helling F, Ragupathi G, Adluri S, Lloyd KO, et al. (1996). Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res 56:3315-3319. (Pubitemid 26242982)